More Than 2,000 Drugs Now in Cancer Immunotherapy Race

December 7, 2017

(Reuters) – The race to develop new immunotherapy treatments against cancer has sparked an unprecedented explosion in the oncology drug pipeline, with more than 2,000 immune system-boosting agents now in development. The result is a scramble for patients to enrol in clinical trials, duplication of effort and the likely ultimate failure of many projects, according to experts.

Recommended Reading